Search Results

The GLP-1 IPO arena has been heating up for the past two years and Metsera’s ask is one the largest in recent history.

William Blair analyst Myles Minter in a Monday note to investors said that Vertex’s povetacicept “has maintained its potential to be a best-in-class asset” in the IgA nephropathy space and could become a “multibillion-dollar pipeline-in-a-drug product” for autoimmune disorders, while “outstanding questions” remain for Biogen’s felzartamab before moving into pivotal studies.

Arena BioWorks announced today its launch as a biomedical research institute with a mission to uncover mechanisms of disease by engaging in basic biological research that will be translated into lifesaving biotech therapeutics.

After being known to have the largest stable in the Weight Management arena, Hi-Tech has cemented its position to become the leader in a new category for focus, concentration, and productivity products with the additional production capacity for Adderex® XR.